IL131448A - Level 1 and level 3 monoclonal antibodies CD23 and their use in drug therapy - Google Patents
Level 1 and level 3 monoclonal antibodies CD23 and their use in drug therapyInfo
- Publication number
- IL131448A IL131448A IL13144898A IL13144898A IL131448A IL 131448 A IL131448 A IL 131448A IL 13144898 A IL13144898 A IL 13144898A IL 13144898 A IL13144898 A IL 13144898A IL 131448 A IL131448 A IL 131448A
- Authority
- IL
- Israel
- Prior art keywords
- human
- antibody
- ige
- gamma
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL15964298A IL159642A0 (en) | 1997-02-20 | 1998-02-17 | Gamma-1 and gamma-3 anti-human cd23 monoclonal antibodies and use thereof as therapeutics |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/803,085 US6011138A (en) | 1997-02-20 | 1997-02-20 | Gamma-1 anti-human CD23 monoclonal antibodies |
US09/019,441 US6893636B2 (en) | 1997-02-20 | 1998-02-05 | Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
PCT/US1998/002253 WO1998037099A1 (en) | 1997-02-20 | 1998-02-17 | Gamma-1 and gamma-3 anti-human cd23 monoclonal antibodies and use thereof as therapeutics |
Publications (2)
Publication Number | Publication Date |
---|---|
IL131448A0 IL131448A0 (en) | 2001-01-28 |
IL131448A true IL131448A (en) | 2004-03-28 |
Family
ID=26692224
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL13144898A IL131448A (en) | 1997-02-20 | 1998-02-17 | Level 1 and level 3 monoclonal antibodies CD23 and their use in drug therapy |
IL15964298A IL159642A0 (en) | 1997-02-20 | 1998-02-17 | Gamma-1 and gamma-3 anti-human cd23 monoclonal antibodies and use thereof as therapeutics |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15964298A IL159642A0 (en) | 1997-02-20 | 1998-02-17 | Gamma-1 and gamma-3 anti-human cd23 monoclonal antibodies and use thereof as therapeutics |
Country Status (14)
Country | Link |
---|---|
US (9) | US6893636B2 (ko) |
EP (2) | EP2103629A1 (ko) |
JP (2) | JP2002514071A (ko) |
KR (1) | KR100697465B1 (ko) |
CN (1) | CN1310947C (ko) |
AU (1) | AU725482B2 (ko) |
BR (1) | BR9807437A (ko) |
CA (1) | CA2281893A1 (ko) |
HK (1) | HK1025978A1 (ko) |
ID (1) | ID23805A (ko) |
IL (2) | IL131448A (ko) |
NO (2) | NO326782B1 (ko) |
NZ (1) | NZ337601A (ko) |
RU (1) | RU2206614C2 (ko) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6893636B2 (en) * | 1997-02-20 | 2005-05-17 | Biogen Idec Ma Inc. | Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
US7033589B1 (en) * | 1997-02-20 | 2006-04-25 | Biogen Idec Ma Inc. | γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
US20030211107A1 (en) * | 2002-01-31 | 2003-11-13 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
JP4571952B2 (ja) * | 2004-02-05 | 2010-10-27 | アクセス ビジネス グループ インターナショナル リミテッド ライアビリティ カンパニー | 抗アレルギー組成物及び関連方法 |
WO2007095230A2 (en) * | 2006-02-13 | 2007-08-23 | The Trustees Of The University Of Pennsylvania | TREATMENT OF AUTOIMMUNE BLISTERING DISEASE USING ANTI-IgE ANTIBODY |
WO2009043051A2 (en) * | 2007-09-27 | 2009-04-02 | Biogen Idec Ma Inc. | Cd23 binding molecules and methods of use thereof |
EA031737B1 (ru) | 2010-06-03 | 2019-02-28 | Фармасайкликс, Инк. | Применение ингибиторов тирозинкиназы брутона (btk) для лечения лейкоза и лимфомы |
CN111234010A (zh) * | 2020-01-20 | 2020-06-05 | 华兰生物工程重庆有限公司 | 降低静注人免疫球蛋白中aca的处理方法 |
CN113980092B (zh) * | 2021-12-09 | 2024-05-14 | 上海药明生物技术有限公司 | 一种蛋白质亲和纯化方法 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3167442D1 (en) * | 1980-07-07 | 1985-01-10 | Nat Res Dev | Improvements in or relating to cell lines |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4629783A (en) * | 1985-04-29 | 1986-12-16 | Genetic Systems Corporation | Synthetic antigen for the detection of AIDS-related disease |
US4714759A (en) * | 1985-12-02 | 1987-12-22 | Whitaker Jr Robert B | Immunotoxin therapy of allergy |
FR2599513B1 (fr) | 1986-05-27 | 1989-09-15 | Unicet Laboratoires | Anticorps monoclonaux inhibant la liaison de ige soluble aux lymphocytes humains, hybridomes monoclonaux produisant de tels anticorps, leur utilisation |
US5635600A (en) | 1986-07-07 | 1997-06-03 | Trustees Of Dartmouth College | Bifunctional and heteroantibodies specific for the high affinity Fc receptor for immunoglobulin G on human mononuclear phagocytes |
SE8701004D0 (sv) | 1987-03-11 | 1987-03-11 | Astra Ab | Method for therapy of leukemias and certain other malignancies |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US4940782A (en) | 1987-06-08 | 1990-07-10 | G. D. Searle & Co. | Monoclonal antibodies against IgE-associated determinants, hybrid cell lines producing these antibodies, and use therefore |
SE459001B (sv) | 1987-07-06 | 1989-05-29 | Gunnar Karl Stroemberg | Anordning med hjul vid tillslutbar lastbehaallare av containertyp med bakre belaegna doerrar |
US5428133A (en) * | 1987-12-31 | 1995-06-27 | Tanox Biosystems, Inc. | Chimeric anti-human IgE-monoclonal antibody which binds to secreted IgE and membrane-bound IgE expressed by IgE-expressing B cells but notto IgE bound to FC receptors on basophils |
US5449760A (en) | 1987-12-31 | 1995-09-12 | Tanox Biosystems, Inc. | Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils |
US4975369A (en) | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
DE3814113A1 (de) | 1988-04-27 | 1989-11-09 | Hal Allergie Gmbh | Physiologisch aktive fluessige wirkstoff-zubereitungen, insbesondere allergen-zubereitung, aus biologischem ursprungsmaterial |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8916400D0 (en) | 1989-07-18 | 1989-09-06 | Dynal As | Modified igg3 |
HUT60768A (en) * | 1990-03-16 | 1992-10-28 | Sandoz Ag | Process for producing cd25 fixing molecules |
WO1992017207A1 (en) * | 1991-03-26 | 1992-10-15 | Tanox Biosystems, Inc. | MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS |
DE4109952A1 (de) | 1991-03-26 | 1992-10-01 | Springfix Befestigungstechnik | Ausgleichsanordnung |
IE922437A1 (en) * | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
US6136310A (en) | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
NZ243706A (en) | 1991-07-25 | 1994-08-26 | Idec Pharma Corp | Recombinant monkey antibodies, pharmaceutical compositions |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
US5914110A (en) * | 1993-09-07 | 1999-06-22 | Smithkline Beecham Corporation | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
DK0788513T3 (da) * | 1994-10-25 | 2001-04-02 | Glaxo Group Ltd | Anvendelse af bindingsmidler for CD23 i behandlingen af atoimmune sygdomme |
US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
US6893636B2 (en) * | 1997-02-20 | 2005-05-17 | Biogen Idec Ma Inc. | Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
US7033589B1 (en) * | 1997-02-20 | 2006-04-25 | Biogen Idec Ma Inc. | γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
US6011138A (en) | 1997-02-20 | 2000-01-04 | Idec Pharmaceuticals Corporation | Gamma-1 anti-human CD23 monoclonal antibodies |
US6127588A (en) * | 1998-10-21 | 2000-10-03 | Phillips Petroleum Company | Hydrocarbon hydrogenation catalyst and process |
US20020006404A1 (en) * | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
US20030211107A1 (en) * | 2002-01-31 | 2003-11-13 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
-
1998
- 1998-02-05 US US09/019,441 patent/US6893636B2/en not_active Expired - Fee Related
- 1998-02-17 IL IL13144898A patent/IL131448A/en not_active IP Right Cessation
- 1998-02-17 RU RU99120076/13A patent/RU2206614C2/ru not_active IP Right Cessation
- 1998-02-17 IL IL15964298A patent/IL159642A0/xx unknown
- 1998-02-17 JP JP53667598A patent/JP2002514071A/ja not_active Withdrawn
- 1998-02-17 ID IDW991061A patent/ID23805A/id unknown
- 1998-02-17 KR KR1020057019831A patent/KR100697465B1/ko not_active IP Right Cessation
- 1998-02-17 CN CNB988043459A patent/CN1310947C/zh not_active Expired - Fee Related
- 1998-02-17 EP EP09156964A patent/EP2103629A1/en not_active Withdrawn
- 1998-02-17 NZ NZ337601A patent/NZ337601A/xx unknown
- 1998-02-17 CA CA002281893A patent/CA2281893A1/en not_active Abandoned
- 1998-02-17 EP EP98906171A patent/EP1019442A1/en not_active Withdrawn
- 1998-02-17 AU AU61469/98A patent/AU725482B2/en not_active Ceased
- 1998-02-17 BR BR9807437-7A patent/BR9807437A/pt not_active IP Right Cessation
-
1999
- 1999-08-19 NO NO19994006A patent/NO326782B1/no not_active IP Right Cessation
-
2000
- 2000-08-23 HK HK00105303A patent/HK1025978A1/xx not_active IP Right Cessation
-
2002
- 2002-03-25 US US10/103,686 patent/US7223392B2/en not_active Expired - Fee Related
-
2004
- 2004-09-28 US US10/951,140 patent/US7332163B2/en not_active Expired - Fee Related
-
2006
- 2006-08-07 US US11/462,984 patent/US20070065435A1/en not_active Abandoned
- 2006-08-07 US US11/462,983 patent/US20070065434A1/en not_active Abandoned
-
2007
- 2007-08-17 US US11/840,656 patent/US20090018314A1/en not_active Abandoned
- 2007-08-17 US US11/840,649 patent/US7695940B2/en not_active Expired - Fee Related
- 2007-08-17 US US11/840,666 patent/US20080193447A1/en not_active Abandoned
- 2007-08-17 US US11/840,665 patent/US20090061511A1/en not_active Abandoned
-
2008
- 2008-09-23 NO NO20084032A patent/NO20084032L/no not_active Application Discontinuation
-
2009
- 2009-12-04 JP JP2009276687A patent/JP2010095526A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6011138A (en) | Gamma-1 anti-human CD23 monoclonal antibodies | |
US7695940B2 (en) | Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics | |
KR102482710B1 (ko) | 항-pd-1 항체, 이의 생산 방법 및 사용 방법 | |
TWI363762B (en) | Antibodies to madcam | |
JP4309383B2 (ja) | ヒト化抗CD11a抗体 | |
KR20010034554A (ko) | 치료제로서의 cd147 결합 분자 | |
SK18122002A3 (sk) | Protilátky proti ľudskému MCP-1 | |
MX2011000616A (es) | Composiciones y metodos de uso para anticuerpos terapeuticos. | |
US7438906B2 (en) | Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics | |
KR100639844B1 (ko) | 감마-1 및 감마-3 항사람 cd23 단클론성 항체 및 치료제로서 이들을 사용하는 방법 | |
MXPA99007688A (en) | Gamma-1 and gamma-3 anti-human cd23 monoclonal antibodies and use thereof as therapeutics | |
US20240034772A1 (en) | Antibodies binding to f-protein of metapneumovirus and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB | Patent renewed | ||
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |